Literature DB >> 1554823

Epidemiology and molecular basis of penicillin-resistant Neisseria meningitidis in Spain: a 5-year history (1985-1989).

J A Sáez-Nieto1, R Lujan, S Berrón, J Campos, M Viñas, C Fusté, J A Vazquez, Q Y Zhang, L D Bowler, J V Martinez-Suarez.   

Abstract

Penicillin-resistant (penr) clinical isolates of Neisseria meningitidis, which do not produce beta-lactamase, were first identified in Spain in 1985; the frequency of their recovery, which has been increasing in the past few years, reached 20% in 1989. Serogrouping, determination of serotypes and subtypes, and multilocus enzyme electrophoresis of the penr strains showed an extensive diversity. Resistance is due, at least in part, to a decreased affinity of penicillin-binding protein (PBP) 2 for penicillin. Similar low-affinity forms of PBP 2 are also found in penr isolates of Neisseria lactamica, Neisseria polysaccharea, and Neisseria gonorrhoeae. Genetic transformation of an N. meningitidis type strain to low-level penicillin resistance with DNA from resistant meningococci and other Neisseria species resulted in transformants that possessed low-affinity forms of PBP 2. These altered forms of PBP 2 have been shown to arise from recombinational events that replace parts of the PBP 2 gene with the corresponding regions from the PBP 2 genes of commensal Neisseria species.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1554823     DOI: 10.1093/clinids/14.2.394

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  28 in total

1.  Complete sequence of a beta-lactamase-encoding plasmid in Neisseria meningitidis.

Authors:  A Bäckman; P Orvelid; J A Vazquez; O Sköld; P Olcén
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

2.  Bacterial Meningitis: Principles and Practical Aspects of Therapy.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

3.  Interlaboratory comparison of agar dilution and Etest methods for determining the MICs of antibiotics used in management of Neisseria meningitidis infections.

Authors:  Julio A Vázquez; Luisa Arreaza; Colin Block; Ingrid Ehrhard; Stephen J Gray; Sigrid Heuberger; Steen Hoffmann; Paula Kriz; Pierre Nicolas; Per Olcen; Anna Skoczynska; Lodewijk Spanjaard; Paola Stefanelli; Muhamed-Kheir Taha; Georgina Tzanakaki
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

4.  Gram-negative Diplococcal Respiratory Infections.

Authors:  Nargis Naheed; Maqsood Alam; Larry I. Lutwick
Journal:  Curr Infect Dis Rep       Date:  2003-06       Impact factor: 3.725

Review 5.  Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.

Authors:  Matthijs C Brouwer; Allan R Tunkel; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

6.  Pattern of bacterial meningitis in Italy, 1994.

Authors:  S Salmaso; P Mastrantonio; G Scuderi; M E Congiu; T Stroffolini; M G Pompa; S Squarcione
Journal:  Eur J Epidemiol       Date:  1997-04       Impact factor: 8.082

7.  International clone of Neisseria meningitidis serogroup A with tetracycline resistance due to tet(B).

Authors:  Sharon A Crawford; Kristin R Fiebelkorn; Jan E Patterson; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

8.  Susceptibility of Neisseria meningitidis to 16 antimicrobial agents and characterization of resistance mechanisms affecting some agents.

Authors:  James H Jorgensen; Sharon A Crawford; Kristin R Fiebelkorn
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

9.  E test as susceptibility test and epidemiologic tool for evaluation of Neisseria meningitidis isolates.

Authors:  J H Hughes; D J Biedenbach; M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

10.  Meningococcal disease and climate.

Authors:  Helena Palmgren
Journal:  Glob Health Action       Date:  2009-11-11       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.